Is Big Pharma dangerously betting on huge, fragile product shots?

Historically, the most significant challenge small biotechs faced was whether to advance a relatively broad portfolio of programs or whether to bet the whole enchilada on a so-called "product shot." 

As I've discussed in context of Peter Sims' wonderful book "Little Bets" (reviewed here), there is a classic tension between investors, who typically favor product shots (since they own a portfolio of small biotechs), and company management, who appropriately worry about risking everything on one program.

It's fascinating to watch how the same challenge appears to be creeping up the food chain, and many big pharmas seem to be investing outlandish amounts of money pursuing similar product shots - Sanofi's recently announced PCSK9 clinical trial is just the latest example.

While no one is suggesting big pharmas are shunting absolutely all of their R&D resources to mega development programs, these companies could clearly fund a number of smaller development programs with the money they are spending on these huge, individual programs.  For all the talk about the age of the blockbuster being over, it's crystal clear that many big pharmas not only remain fixated on blockbusters but feel confident they can identify them.  

Mathematically, they clearly believe the commercial potential in these cases justifies the huge development costs and sizable risks, and feel that the potential exceeds that of the multiple other programs they could theoretically be resourcing instead (unless you have an even more cynical view, and believe they are pushing these huge programs because they have so little else worthwhile to fund).

I am struck by the difficulty of prediction, as I've discussed both recently, and also several years ago (with Nassim Taleb) here.  Advancing a small number of large, intricate programs also seems like a vivid example of the sort of dangerously excessive investment in the highly fragile that Taleb inveighs against.

It will be interesting to see how these giant bets turn out.

 

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

David
Shaywitz

What's new on AEI

Making Ryan's tax plan smarter
image The teacher evaluation confronts the future
image How to reform the US immigration system
image Inversion hysteria
AEI on Facebook
Events Calendar
  • 01
    MON
  • 02
    TUE
  • 03
    WED
  • 04
    THU
  • 05
    FRI
Wednesday, September 03, 2014 | 9:00 a.m. – 10:30 a.m.
From anarchy to Augustus: Lessons on dealing with disorder, from Rome’s first emperor

We invite you to join us for two panel discussions on how Augustus created order from chaos 2,000 years ago, and what makes for durable domestic and international political systems in the 21st century.

Event Registration is Closed
Wednesday, September 03, 2014 | 12:00 p.m. – 1:30 p.m.
Multiple choice: Expanding opportunity through innovation in K–12 education

Please join us for a book launch event and panel discussion about how a marketplace of education options can help today's students succeed in tomorrow's economy. Attendees will receive a complimentary copy of the featured book.

Thursday, September 04, 2014 | 12:00 p.m. – 1:30 p.m.
How conservatives can save the safety net

Please join us for a luncheon event in which our panel will discuss what conservatives can learn from how liberals talk and think about the safety net and where free-market economics, federalism, and social responsibility intersect to lift people out of poverty.

No events scheduled this day.
No events scheduled this day.
No events scheduled today.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.